Story

Micron Stock Declines Amid Profit-Taking and Rising Competitive Concerns

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Micron Stock Declines Amid Profit-Taking and Rising Competitive Concerns

Summary

Shares of Micron Technology fell as investors secured profits following a recent record high, with growing concerns over DRAM supply and potential price moderation weighing on sentiment.

Text size
Background

Shares of Micron Technology (NASDAQ: MU) declined Tuesday morning, falling 5.1% as investors took profits after a significant rally that pushed the stock to an all-time high in late June. The sell-off is occurring even as the broader market indexes trade higher, indicating pressure specific to the semiconductor sector.

Competitive and Pricing Headwinds

A key factor weighing on investor sentiment is the recent Nasdaq debut of South Korean competitor SK Hynix. The rival memory maker has outlined plans to significantly expand its DRAM production capacity, raising concerns about a potential increase in future supply that could pressure chip prices.

Adding to these concerns are reports that AI cloud computing company CoreWeave is exploring financial derivatives, such as put options, to hedge against potential declines in memory chip prices. This move suggests that major customers may be anticipating a moderation in the elevated pricing environment that has recently fueled Micron's growth.

Sample IUX Markets – In-articleAd

Market and Sector Context

The weakness in Micron's stock is part of a broader, near-term downturn in the semiconductor industry. The Philadelphia Semiconductor Index has corrected more than 14% from its late-June highs. From a technical perspective, Micron's stock has fallen roughly 19% from its recent record and is trading below its 20-day simple moving average.

The selling pressure has so far outweighed recent optimism from Wall Street. On Tuesday, KeyBanc raised its price target on Micron to $1,750 from $1,600, citing expectations of a tight memory market through 2027. However, this bullish call was not enough to reverse the day's negative momentum.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST